May. 14 at 3:43 PM
$ABUS seems likely they would want to partner with
$BRNS for VTP-300 based on the recently presented HBV data from IM-PROVE P2a clinical trial based on the ability to achieve functional cures with imdusiran + VTP-300 + low-dose nivolumab in pts with low baseline HBsAg levels <1000.
Even better for
$ABUS to make an all-stock buyout offer for
$BRNS to expand pipeline and nearly double their cash with
$BRNS reporting over
$100 million cash at end of Q1 with just over 40 million shares outstanding.
Saying this fully biased and long
$BRNS but think it would benefit
$ABUS if they made the deal.
$BRNS has stated they are in ongoing partnership discussions for VTP-300 and are focusing resources on SNAP-TI platform with lead celiac disease immune tolerance program to begin generating data in Q3.
$BRNS has proven track record of developing AZN's COVID vaccine, VAXZEVRIA, along with Oxford University Innovation and Oxford Science Enterprises holds nearly 22% of shares.
